2 absence of Vertical Transmission.

- 4 Nadia M. Ikumi<sup>1</sup>, Komala Pillay<sup>2,3</sup>, Tamara Tilburgs<sup>4,5</sup>, Thokozile R. Malaba<sup>6</sup>,
- 5 Sonwabile Dzanibe<sup>1</sup> Elizabeth Ann L Enninga<sup>7</sup>, Rana Chakraborty<sup>7,8,9</sup>, Mohammed
- 6 Lamorde<sup>10</sup>, Landon Myer<sup>6</sup>, Saye Khoo<sup>11</sup>, Heather B Jaspan<sup>1</sup> and Clive M. Gray<sup>1,2,12\*</sup>,
- 7 for the DolPHIN-2 Study Group
- <sup>9</sup> Division of Immunology, Institute of Infectious Disease and Molecular Medicine,
- 10 University of Cape Town, South Africa
- <sup>2</sup>National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South
- 12 Africa

1

3

- <sup>3</sup>Division of Anatomical Pathology, Department of Pathology, University of Cape
- 14 Town, Cape Town, South Africa
- <sup>4</sup>Division of Immunobiology, Center for Inflammation and Tolerance, Cincinnati
- 16 Children's Hospital, Cincinnati OH 45229, USA
- <sup>5</sup>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati
- 18 OH 45229, USA
- 19 <sup>b</sup>Division of Epidemiology and Biostatistics, School of Public Health and Family
- 20 Medicine, University of Cape Town, Cape Town, South Africa
- <sup>7</sup>Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905
- 22 \*Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine
- and Science, Minnesota, USA
- <sup>9</sup>Department of Immunology, Mayo Clinic, Rochester, MN 55905

Word count: Abstract: 206 words, Lay abstract: 192 words; Main text 3494; 48

references; 5 Figures and 2 Tables; supplementary figures <25MB

34

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

3

**ABSTRACT** Background: Implementation of universal antiretroviral therapy (ART) has significantly lowered vertical transmission rates but has also increased numbers of HIV-exposed uninfected children (HEU), who remain vulnerable to morbidities. Here, we investigated whether T cell alterations in the placenta contribute to altered immune status in HEU. Methods: We analyzed T cells from term placentae decidua and villous tissue and paired cord blood from pregnant women with HIV (PWH) who initiated ART late in pregnancy (n=21) with pregnant women not living with HIV (PWNH) (n=9). Results: Placentae from PWH showed inverted CD4:CD8 ratios and higher proportions of tissue resident CD8+ T cells in villous tissue relative to control placentae. CD8+ T cells in the fetal capillaries, which were of fetal origin, positively correlated with maternal plasma viraemia prior to ART initiation, implying that imbalanced T cells persisted throughout pregnancy. Additionally, the expanded memory differentiation of CD8+ T cells was confined to the fetal placental compartment and cord blood but was not observed in the maternal decidua. Conclusions: T cell homeostatic imbalance in the blood circulation of PWH is reflected in the placenta. The placenta may be a causal link between HIV-induced maternal immune changes during gestation and altered immunity in newborn infants in the absence of vertical transmission. Keywords: CD4, CD8, T cells, placenta, HIV, HEU, HIV-exposed, placenta pathology, villous tissue

## Lay Summary

The effective prevention of HIV transmission during pregnancy with the rollout of antiretroviral therapy (ART) has resulted in increased numbers of HIV-exposed uninfected children (HEU). These children are vulnerable to infections and health problems and have distorted cellular immune systems at birth. We investigated whether these immune alterations originate in the placenta, as this fetal organ maintains life during pregnancy. After collecting placentae at term from pregnant women living with HIV (PWH), who started ART in the third trimester (n=21) and from pregnant women not living with HIV (PWNH) (n=9), we isolated T cells from dissected placental tissue and matching cord blood. Placentae from PWH showed inverted CD4:CD8 ratios in the placenta and cord blood with higher numbers of CD8+ T cells in the fetal part of the placenta. These CD8+ T cells mirrored events in the blood circulation of the mother and the altered balance of T cell immunity in the PWH was reflected in the placenta. Accordingly, the placenta may be a pivotal link between HIV-induced maternal immune changes and altered immunity in newborn infants in the absence of vertical transmission.

#### Background

In adults, HIV causes severe immune dysregulation, characterized by systemic depletion of CD4+ T cells, increased HIV-1 specific CD8+ T cells, inflammation and a progressive failure of the immune system[1–3]. Initiation of antiretroviral therapy (ART) has been shown to augment HIV-specific CD4+ T cell responses, but normalization of the CD4:CD8 T cell ratio does not occur in a large proportion of people with HIV[4]. In pregnant women living with HIV (PWH), there is evidence that women who initiate ART before pregnancy are more likely to have adverse birth outcomes compared to initiation during pregnancy [5].

Placentae from PWH exhibit increased signs of inflammation and injury affecting maternal vasculature and circulation[6,7]. Studies also show that using protease inhibitor-based ART during pregnancy associates with placental injury affecting maternal vascularization and impaired decidualization [8,9]. In addition, although the maternal and fetal circulation within the placenta takes place in distinct compartments, there is evidence that maternal HIV and viral load impacts the fetal immune system. HIV-exposed uninfected children (HEU) have been shown to have lower CD4 T cells and CD4:CD8 T cell ratios at birth [10,11] and this appears to be related to maternal viral loads above 1000 RNA copies/ml [12]. HIV-unexposed uninfected children (HUU) have an almost completely naïve T cell repertoire, but at birth HEU can have increased proportions of differentiated immune cells suggestive of antigen experience *in utero*[10,13]. Indeed, a number of factors including impaired thymic output and functioning may underlie the immune alterations in HEU[14,15]. Here, we sought to investigate how HIV exposure *in utero* may contribute to altered HEU immunity[16,17].

To test the hypothesis that maternal HIV infection is associated with disruption of T cell homeostasis in the placenta and cord blood from HEU newborns, we examined term placentae from PWH from a randomized trial in pregnant mothers initiating dolutegravir versus efavirenz-containing therapy in the third trimester (DolPHIN-2: NCT03249181)[18], as well as pregnant women not living with HIV (PWNH), controls. We show that placentae from PWH have inverted CD4:CD8 ratios with higher CD8+ T cells in villous tissue relative to control placentae contributing to T cell homeostatic imbalance in the placenta at birth.

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

7

Methods Cohort We included 21 placentae with 9 paired cord blood samples from PWH and HEU and 9 placentae from PWNH with 5 cord blood samples from HUU in this study. The PWH group was nested in the DolPHIN-2 study recruited from the Gugulethu Community Health Centre, Cape Town[18]. PWNH were enrolled from Khayelitsha Site B Midwife Obstetric Unit, Cape Town. All placentae were from term deliveries (>37 weeks' gestation). Clinical Data collection As part of DolPHIN-2, maternal systemic CD4 T cell counts and plasma viral loads (VL) copies were measured at ART initiation at 28 weeks' gestation (visit 1), 29 weeks (visit 2), 33 weeks (visit 3), 36 weeks (visit 4) and day 14 after delivery (visit 5). The level of HIV-1 RNA detection was 50 copies per ml[18]. Placenta and cord blood processing. Cells were isolated from each placenta as previously described[19] and illustrated in Supplementary Figure 1. Placentae were collected in RPMI 1640 supplemented with 10% fetal calf serum and penicillin/streptomycin at room temperature and processing was performed within six hours of delivery. Each placenta was dissected to obtain the decidua parietalis, basalis and villous tissue. Enzymatic lymphocyte isolation was performed using Collagenase I and DNAse I. The lymphocyte fraction was obtained following Percoll density centrifugation and incubated with violet amine reactive viability dye (VIVID, Thermofisher). The cells were then fixed using BD FACS™

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

8

followed by varying concentrations of alcohol and then incubated in 3% hydrogen

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

9

peroxide. Heat-mediated antigen retrieval was performed using an EDTA buffer (pH9). The slides were then incubated with 1% Bovine Serum Albumin and stained with anti-CD8. The images were acquired on Zeiss Axioskop 200 upright Fluorescence microscope with an AxioCam high resolution colour (HRC) camera. Fluorescence in situ hybridization (FISH) As there were five male babies, we selected those placental samples to identify the origin of the infiltrating lymphocytes by looking for the Y chromosome using XY-FISH. Briefly, the slides were baked at 90°C for 15 minutes, deparaffinized in xylene. dehydrated in 100% ethanol and then placed in 10mM Citric Acid (pH 6.0). The slides were then dehydrated in varying concentrations of ethanol (70%, 85% and 100%). We then applied a working solution of DXZ1/DYZ3 (Abbott Laboratories, Des Plaines, IL, USA) to the target areas, co-denatured with a ThermoBrite (Abbott Laboratories) and hybridized overnight at 37°C. The slides were then counter stained with 4'-6'-diamidino-2-phenylindole (DAPI) (Vector Laboratories). Tissue samples were scanned and the qualitative result was determined based on observed signal patterns by CytoVision (Leica Biosystems, Germany). Statistics All flow cytometry data were analyzed using FlowJo version 10 (Treestar). Statistical analyses were performed using Prism version 8 (Graphpad Software), STATA version 12.0 (Stata Corporation) or R[22]. Immunohistochemistry cell counts were performed using Image J Fiji version 2 (WS Rasband, National Institute of Health). Tests of significance were performed using Mann-Whitney U and Kruskal-Wallis

tests for intergroup comparisons. The associations between cell proportions and

Study approval

The study protocol, informed consent and all data collection tools were approved by the University of Cape Town, Human Research Ethics Committee (096/2017). Written and signed informed consent was obtained from all participants, including collection of placentae prior to study inclusion.

#### Results

Participant Characteristics

Maternal and newborn infant characteristics are shown in Table 1. No significant differences in maternal age were noted between PWNH and PWH at enrolment, with the median gestational age (GA) being 30 weeks and 28 weeks between the groups. PWH were more likely to be multigravida (p=0.003). Median GA at delivery was 40 weeks in PWNH and 39 weeks in the PWH (p=0.03) and there was a lower birthweight trend in HEU (p=0.07). We collected placentae from 21 PWH: 16 (76.2%) receiving efavirenz (EFV+TDF+3TC) and 5 (23.8%) receiving dolutegravir (DTG+TDF+3TC), shown in Supplementary Table 1. Median CD4 count at ART initiation was 358 cells/mm³ (IQR 278–477), with no difference between ART groups (Supplementary Table 2). The median VL at ART initiation was 4.54 log<sub>10</sub> RNA copies/ml (IQR 3.85–4.80) in the EFV group versus 3.83 log<sub>10</sub> RNA copies/ml (3.49–3.83) in the DTG group, with a combined viraemia of 4.28 log<sub>10</sub> RNA copies/ml

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

11

PWNH. The proportion of CD8+ T cells was significantly increased (Figure 1A) in all

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

12

As expected, the enrolment plasma viraemia, ranging from 1.69 - 6.0 log<sub>10</sub> RNA

Immunohistochemistry confirms anatomical location and fetal origin of CD8+ T cells

in villous tissue

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

Analysis of placental villi from 13 PWH and 3 PWNH controls showed the presence of CD8+ cells in the fetal capillaries (Figure 3A). The numbers of CD8+ T cells positively correlated with pre-ART maternal viremia (Figure 3B), confirming the flow cytometric analysis (Figures 1A, 2D). Using FISH to detect X and Y chromosomes in cells located within the villi from 5 placentae with male births, we confirmed the presence of male (fetal) cells in fetal capillaries (Figure 3C). Thus, the immunohistochemistry analysis confirms the anatomical location and fetal origin of the increased proportions of CD8+ T cells in villous tissue. The fetal (male) origin of

the CD8+ T cells in placental villi is consistent with the absence of villitis of unknown etiology (VUE), a lesion that is characterized by maternal immune infiltrates[23,24]. HIV exposure increases differentiation of CD8+ T cells in placental villi and fetal cord blood, but not in the maternal placental compartments CD45RA and CD28 were used to identify the proportions of naïve (CD45RA+CD28+), early differentiated (ED, CD45RA-CD28+), late differentiated (LD, CD45RA-CD28-) and terminally differentiated (TD, CD45RA+CD28-) memory CD4+ and CD8+ T cells from villous tissue and matching cord blood (Figure 4A). We observed significantly lower proportions of naïve CD8+ T cells and significantly higher proportions of LD CD8+ T cells in villous tissue and cord blood of HEU compared to HUU (Figure 4B). The CD4+ T cells in the villous tissue were predominantly of a naïve and ED phenotype while the cord blood cells were predominantly naïve. There were no significant differences in CD4+ T cell differentiation state based on HIV-exposure (Supplementary Figure 9). In addition, no significant differences in the stage of CD4+ and CD8+ T cell differentiation in the decidua was observed between the HIV groups (Supplementary Figure 10). Thus, the increased differentiation state of CD8+ T cells is confined to the fetal placental and cord blood compartments and not observed in the maternal placental compartments. There was no correlation between maternal pre-ART viremia and memory stage of CD8+ T cells in placental villous tissue and cord blood (data not shown). We additionally showed that there was no association between villous tissue CD8+ T cell memory differentiation and reported adverse events in the infant during

the first 12 weeks of life (Supplementary Figure 11).

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

#### Discussion

We present data from a unique cohort of PWH who initiated ART late in pregnancy and show that maternal HIV infection has a clear impact on T cell subsets in the decidua, villous tissue and cord blood. As the decidua and decidual immune cells are of maternal origin, it may not be surprising to find such a footprint[25]. Maternal HIV infection likely affects and kills maternal decidual CD4+ T cells and fewer peripheral blood T cells may traffic to decidual tissue; chemokine gradients have been shown to play a key role in the trafficking of maternal T cells into the decidua during pregnancy[26]. We show that in contrast to the decidua, the inverted CD4:CD8 ratio in the villous tissue was largely due to an increased proportion of CD8+ T cells and not, as observed in the other tissues, due to a decrease in CD4+ T cells. These CD8+ T cells were of an early-late differentiated phenotype, suggestive of previous antigen experience[27,28].

The human placenta has two circulatory compartments: the utero-placental unit for the trafficking of maternal blood and the feto-placental unit for the fetal blood circulation[29,30]. Therefore, cells in the villous tissue are likely to be predominantly from the placental reservoir. A key question is whether the increased CD8+ T cell differentiation in villi and cord blood is due to direct exposure to HIV antigens, presence of other pathogens (e.g. CMV) or increased levels of other non-infectious inflammatory cues in placentae of PWH. Viral particles, structural and core HIV proteins have been shown to cross the placental barrier in the absence of fetal infection leading to altered immune profiles in HEU infants[31,32]. A number of studies also describe HIV-specific T cell responses in HEU infants, possibly primed by exposure to HIV antigens in utero [16,33,34].

The lower proportion of naïve cells and increased memory T cells reflected in villous tissue and cord blood mirror previous studies; HEU infants have been shown to have reduced CD4+ T cell numbers and increased CD8+ T cells compared to HUU infants at birth[35,36]. HEU infants have also been shown to have lower naïve cells thought to be due to thymic involution and frequent stimulation and expansion of the antigenspecific T cells in an effort to regenerate the T cell pool[14,15]. Whether the same findings would be recapitulated in PWH with preconception suppressed viral loads is unknown. Nevertheless, this study afforded us a unique opportunity to investigate the impact of starting ART late in pregnancy and how this affected placental immunity. Being able to compare this with women who are consistently on ART throughout pregnancy would reveal whether long-term viral suppression creates a more normalized immune balance in the placenta.

It was not possible to tease out the impact between HIV and ART on the placenta/fetus. There is evidence that some ART can cross the placenta [37,38]. Additional studies show that perinatal drug exposure associates with lower T cell counts in the first two years in HEU infants[39]. Although we cannot discount the effect of ART alone on the placenta, the parent study did report on minimal effects of ART on the newborn child[18]. A limitation of our study was only having maternal CD4 and CD8 T cell counts at week 28 gestation in PWH and no equivalent measures in PWNH. We therefore could not directly compare the impact of HIV/ART exposure on systemic T cells compared to placental T cells at delivery and nor in healthy mothers.

Here, we demonstrate that within the feto-placental unit, there are differences between the T cell profiles in the villi and cord blood. We postulate that the cells we characterized in the villi may be a combination of cells within the villi, and cells attached to the fetal capillaries. Contaminating circulating cord blood cells in this fraction cannot be completely ruled out but is minimized by extensive washing of the tissues prior to isolation. Moreover, the phenotypic differences between villous and cord blood T cells as presented here suggest that the villous T cells do not include large proportions of circulating T cells. The increased differentiation state of CD8+ T cells in the villi may be due to exposure to antigens within the villous microenvironment as well as the mechanisms of immune activation leading to T cells adhesion and extravasation. Attempts to make a direct connection between the elevated numbers and proportions of CD8+ T cells found in the villous tissue with

adverse health events in the first few weeks after birth, revealed no association; most events were resolving rashes.

Of particular note, women were ART naïve during the first and second trimester and it is likely that prolonged HIV exposure may have contributed to altered placental development and the significantly lower placental weight observed. Interestingly, all cases of maternal vascular malperfusion (MVM) were reported in placentae from PWH and possibly reflects placental injury affecting maternal vasculature and perfusion and increasing the risk of an adverse birth outcome[42]. We have previously reported on MVM in placentae from PWH on long-term ART, an incidence of about 27% overall, similar to Kalk *et al* [6,21]. It is likely that HIV and/or ART exposure alters factors involved in vascular development, resulting in placental insufficiency and increased risk of adverse birth outcomes[8,9,43].

In conclusion, we provide evidence that *in utero* exposure to HIV results in an altered immune balance in both the utero-placental and feto-placental compartments. Despite the initiation of ART in the third trimester, resulting in either full or partial maternal viral suppression by the time of delivery, there was a significant imbalance in term placental T cell homeostasis and to a lesser degree in the cord blood. Overall, our results suggest that maternal immunity leaves a footprint in the placenta that may shape the neonatal/infant immune landscape.

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

20

**Footnotes** Conflict of interest statement The authors have declared that no conflict of interest exists. **Funding** This research was supported by a Fellowship to NMI from the AXA Research Fund, Paris and partly through R01HD102050-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of those of the AXA Research Fund. The research is part of the DOLPHIN-2 clinical trial sponsored by UNITAID (ClinicalTrials.gov NCT03249181). **Corresponding Author** Clive M Gray, Division of Immunology, Institute of Infectious Disease and Molecular Medicine, Falmouth Building, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town, South Africa, 7925; Tel: +27 21 406 6616; Email: clive.gray@uct.ac.za

## **Figure Legends**

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

### Figure 1: Proportions of T cells in the placenta and cord blood

(A) Box plots (showing medians and interquartile ranges) of CD3+CD4+CD8- T cells and CD3+CD4-CD8+ T cell proportions isolated from the decidua parietalis, decidua basalis, villous tissue and cord blood from Pregnant Women not living with HIV (PWNH) and Pregnant Women with HIV (PWH) and HIV unexposed uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. (B) Box plots (showing medians and interquartile ranges) of CD4:CD8 T cell ratios in the decidua parietalis, decidua basalis, villous tissue and cord blood from Pregnant Women not living with HIV (PWNH) and Pregnant Women with HIV (PWH) and HIV unexposed and uninfected (HUU) and HIV exposed uninfected (HEU) cord bloods. Tests of significance were performed using the Mann-Whitney U test. (C) Correlation plots between the absolute maternal CD4 count at 28 weeks' gestation prior to ART initiation and the proportion of CD4+ T cells isolated from the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey shaded areas represent the 95% confidence intervals. (D) Correlation plots between the absolute maternal CD4 count at 28 weeks' gestation prior to ART initiation and the proportion of CD8+ T cells isolated from the decidua parietalis, basalis, villous tissue and cord blood. Statistical analysis was performed using the Spearman rank test and the grey shaded areas represent the 95% confidence intervals.

# Figure 2: Proportions of CD4+ and CD8+ T cells in the placenta and maternal

### 466 viral load

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

22

#### Figure 3: Anatomical location of CD8+ T cells in the villous tissue

rank test and the grey shaded area represents the 95% confidence intervals.

(A) Representative immunohistochemical stained images of CD8+ T cells in villous tissue sections denoted in brown dots and black arrows in the villi of placentae from HIV-infected and –uninfected mothers (40x magnification). (B) Correlation plot between the density of tissue-bound CD8+ T cells in the villi and maternal viral load at ART initiation (pre-ART). Statistical analysis was performed using the Spearman

Representative Fluorescence in situ Hybridization (FISH) images of lymphocytes

(white arrows) in the villous tissue from placentas from male infants. The X

chromosome is denoted in green and Y chromosome denoted in red (digitally

scanned slides).

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

## Figure 4: Memory phenotype of CD4 and CD8 T cells in the Villous Tissue

(A) Representative flow cytometry contour plots of Naïve, Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) CD4+ T cells and CD8+ T cells in the villous tissue (VT; upper panel) of placentae from PWNH and PWH and

cord blood from HIV unexposed and uninfected (HUU) and HIV exposed uninfected

(HEU). (B) Box plots (showing medians and interquartile ranges) of CD8+ Naïve,

Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) T

cells in the villous tissue and cord blood from HIV unexposed and uninfected (HUU)

and HIV exposed uninfected (HEU). Tests of significance were performed using the

Mann-Whitney *U* test.

#### **Supplementary Figures**

#### Supplementary Figure 1: Lymphocyte isolation from the human placenta

Stepwise isolation of lymphocytes from the human placenta decidua parietalis (DP),

decidua basalis (DB) and villous tissue (VT): (1) dissection of the whole placenta; (2)

multiple rounds of maternal blood rinsing to avoid contamination followed by

enzymatic digestion of each dissected tissue; (3) lymphocyte separation obtained by

Percoll density centrifugation; (4) cryopreservation of fixed cells and

immunophenotyping using flow cytometry. Image created with Biorender.com.

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

24

(PWNH) and Pregnant Women with HIV (PWH). Tests of significance were

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

25

blood. Statistical analysis was performed using the Spearman rank test and the grey

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

26

cells in the decidua parietalis and basalis of placentae from PWNH and PWH. (B)

Box plots (showing medians and interquartile ranges) of CD4+ and (C) CD8+ Naïve, Early differentiated (ED), Late differentiated (LD) and Terminally differentiated (TD) T cells in the decidua parietalis and basalis of placentae from PWNH and PWH.

Supplementary Figure 11: Proportion of CD8+ T cells in the Villous Tissue and Adverse Events in HEU in the first three months of life.

Scatter plot showing the proportion of CD8+ T cells delineated by naïve, early differentiated memory, late differentiated and terminally differentiated memory in HEU infants comparing adverse events with no events reported.

#### References

- 1. Okoye AA, Picker LJ. CD4 + T-cell depletion in HIV infection: mechanisms of
- immunological failure. Immunol Rev [Internet]. 2013 Jul;254(1):54–64.
- Available from: http://doi.wiley.com/10.1111/imr.12066
- 607 2. Demers KR, Makedonas G, Buggert M, et al. Temporal Dynamics of CD8+ T
- 608 Cell Effector Responses during Primary HIV Infection. Douek DC, editor.
- 609 PLOS Pathog [Internet]. 2016 Aug 3;12(8):e1005805. Available from:
- 610 http://dx.plos.org/10.1371/journal.ppat.1005805
- 611 3. Hileman CO, Funderburg NT. Inflammation, Immune Activation, and
- Antiretroviral Therapy in HIV. Curr HIV/AIDS Rep [Internet]. 2017;14(3):93–
- 613 100. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28434169
- 614 4. Okhai H, Vivancos-Gallego MJ, Hill T, Sabin CA. CD4+:CD8+ T Cell Ratio
- Normalization and the Development of AIDS Events in People with HIV
- Starting Antiretroviral Therapy. AIDS Res Hum Retroviruses [Internet]. 2020
- Oct 1;36(10):808–16. Available from:
- 618 https://www.liebertpub.com/doi/10.1089/aid.2020.0106
- 5. Uthman OA, Nachega JB, Anderson J, et al. Timing of initiation of antiretroviral
- therapy and adverse pregnancy outcomes: a systematic review and meta-
- analysis. Lancet HIV [Internet]. 2017 Jan;4(1):e21–30. Available from:
- https://linkinghub.elsevier.com/retrieve/pii/S2352301816301953
- 623 6. Kalk E, Schubert P, Bettinger JA, et al. Placental pathology in HIV infection at
- term: a comparison with HIV-uninfected women. Trop Med Int Health [Internet].
- 625 2017;22(5):604–13. Available from:
- http://www.ncbi.nlm.nih.gov/pubmed/28214384
- 7. Mwanyumba F, Gaillard P, Inion I, et al. Placental Inflammation and Perinatal

628 Transmission of HIV-1. JAIDS J Acquir Immune Defic Syndr [Internet]. 2002 629 Mar;29(3):262–9. Available from: http://journals.lww.com/00126334-630 200203010-00006 631 Mohammadi H, Papp E, Cahill L, et al. HIV antiretroviral exposure in 8. 632 pregnancy induces detrimental placenta vascular changes that are rescued by 633 progesterone supplementation. Sci Rep [Internet]. 2018 Dec 26;8(1):6552. 634 Available from: http://www.nature.com/articles/s41598-018-24680-w 635 9. Kala S, Dunk C, Acosta S, Serghides L. Periconceptional exposure to 636 lopinavir, but not darunavir, impairs decidualization: a potential mechanism 637 leading to poor birth outcomes in HIV-positive pregnancies. Hum Reprod 638 [Internet]. 2020 Aug 1;35(8):1781–96. Available from: 639 https://academic.oup.com/humrep/article/35/8/1781/5876549 640 10. Clerici M, Saresella M, Colombo F, et al. T-lymphocyte maturation 641 abnormalities in uninfected newborns and children with vertical exposure to 642 HIV. Blood [Internet]. 2000 Dec 1;96(12):3866–71. Available from: 643 http://www.ncbi.nlm.nih.gov/pubmed/11090071 644 Abu-Raya B, Kollmann TR, Marchant A, MacGillivray DM. The Immune 11. 645 System of HIV-Exposed Uninfected Infants. Front Immunol [Internet]. 646 2016;7:383. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27733852 647 12. Kakkar F, Lamarre V, Ducruet T, et al. Impact of maternal HIV-1 viremia on 648 lymphocyte subsets among HIV-exposed uninfected infants: protective 649 mechanism or immunodeficiency. BMC Infect Dis [Internet]. 2014 May 650 5;14:236. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24885498 651 13. Ono E, Santos AMN dos, Succi RC de M, et al. Imbalance of naive and 652 memory T lymphocytes with sustained high cellular activation during the first

653 year of life from uninfected children born to HIV-1-infected mothers on HAART. 654 Brazilian J Med Biol Res [Internet]. 2008 Aug;41(8):700–8. Available from: 655 http://www.scielo.br/scielo.php?script=sci arttext&pid=S0100-656 879X2008000800011&Ing=en&tIng=en Mansoor N, Abel B, Scriba TJ, et al. Significantly skewed memory CD8+ T cell 657 14. 658 subsets in HIV-1 infected infants during the first year of life. Clin Immunol 659 [Internet]. 2009 Mar;130(3):280–9. Available from: 660 http://www.ncbi.nlm.nih.gov/pubmed/18996749 661 15. Akbar AN, Fletcher JM. Memory T cell homeostasis and senescence during 662 aging. Curr Opin Immunol [Internet]. 2005 Oct;17(5):480–5. Available from: 663 http://www.ncbi.nlm.nih.gov/pubmed/16098721 664 16. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-665 Jones SL. HIV-exposed uninfected children: a growing population with a 666 vulnerable immune system? Clin Exp Immunol [Internet]. 2014 Apr;176(1):11-667 22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24325737 668 Slogrove AL, Powis KM, Johnson LF, Stover J, Mahy M. Estimates of the 17. 669 global population of children who are HIV-exposed and uninfected, 2000–18: a 670 modelling study. Lancet Glob Heal [Internet]. 2020 Jan;8(1):e67-75. Available 671 from: https://linkinghub.elsevier.com/retrieve/pii/S2214109X19304486 672 18. Kintu K. Malaba TR. Nakibuka J. et al. Dolutegravir versus efavirenz in women 673 starting HIV therapy in late pregnancy (DoIPHIN-2): an open-label, randomised 674 controlled trial. Lancet HIV [Internet]. 2020 May;7(5):e332–9. Available from: 675 https://linkinghub.elsevier.com/retrieve/pii/S2352301820300503 676 19. Tilburgs T, Crespo ÂC, van der Zwan A, et al. Human HLA-G+ extravillous 677 trophoblasts: Immune-activating cells that interact with decidual leukocytes.

678 Proc Natl Acad Sci [Internet]. 2015 Jun 9;112(23):7219–24. Available from: 679 http://www.pnas.org/lookup/doi/10.1073/pnas.1507977112 680 20. Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental 681 Lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch. 682 Pathol Lab Med [Internet]. 2016 Jul;140(7):698–713. Available from: 683 http://www.archivesofpathology.org/doi/10.5858/arpa.2015-0225-CC 684 21. Ikumi NM, Malaba TR, Pillay K, et al. Differential impact of antiretroviral 685 therapy initiated before or during pregnancy on placenta pathology in HIV-686 positive women. AIDS [Internet]. 2021 Feb 3; Publish Ah. Available from: 687 https://journals.lww.com/10.1097/QAD.000000000002824 688 22. R Core Team. R: A language and environment for statistical computing 689 [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2020. 690 Available from: https://www.r-project.org/ 691 23. Enninga EAL, Raber P, Quinton RA, et al. Maternal T Cells in the Human 692 Placental Villi Support an Allograft Response during Noninfectious Villitis. J 693 Immunol [Internet]. 2020 Jun 1;204(11):2931–9. Available from: 694 http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1901297 695 Tamblyn JA, Lissauer DM, Powell R, Cox P, Kilby MD. The immunological 24. 696 basis of villitis of unknown etiology – Review. Placenta [Internet]. 2013 697 Oct;34(10):846–55. Available from: 698 https://linkinghub.elsevier.com/retrieve/pii/S0143400413005894 699 25. Ander SE, Diamond MS, Coyne CB. Immune responses at the maternal-fetal 700 interface. Sci Immunol [Internet]. 2019 Jan 11;4(31):eaat6114. Available from: 701 http://immunology.sciencemag.org/lookup/doi/10.1126/sciimmunol.aat6114 702 26. Huang Y, Zhu X-Y, Du M-R, Li D-J. Human trophoblasts recruited T

703 lymphocytes and monocytes into decidua by secretion of chemokine CXCL16 704 and interaction with CXCR6 in the first-trimester pregnancy. J Immunol 705 [Internet]. 2008 Feb 15;180(4):2367–75. Available from: 706 http://www.ncbi.nlm.nih.gov/pubmed/18250446 707 Tilburgs T, Strominger JL. CD8+ Effector T Cells at the Fetal-Maternal 27. 708 Interface, Balancing Fetal Tolerance and Antiviral Immunity. Am J Reprod 709 Immunol [Internet]. 2013 Apr;69(4):395–407. Available from: 710 http://doi.wiley.com/10.1111/aji.12094 711 28. White JT, Cross EW, Kedl RM. Antigen-inexperienced memory CD8+ T cells: 712 where they come from and why we need them. Nat Rev Immunol [Internet]. 713 2017 Jun;17(6):391–400. Available from: 714 http://www.ncbi.nlm.nih.gov/pubmed/28480897 715 29. Dawe GS, Tan XW, Xiao Z-C. Cell migration from baby to mother. Cell Adh 716 Migr [Internet]. 2007;1(1):19–27. Available from: 717 http://www.ncbi.nlm.nih.gov/pubmed/19262088 718 30. Acharya G, Sonesson S-E, Flo K, Räsänen J, Odibo A. Hemodynamic aspects 719 of normal human feto-placental (umbilical) circulation. Acta Obstet Gynecol 720 Scand [Internet]. 2016 Jun;95(6):672–82. Available from: 721 http://doi.wiley.com/10.1111/aogs.12919 722 Nielsen SD, Jeppesen DL, Kolte L, et al. Impaired progenitor cell function in 31. 723 HIV-negative infants of HIV-positive mothers results in decreased thymic 724 output and low CD4 counts. Blood [Internet]. 2001 Jul 15;98(2):398–404. 725 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11435309 726 32. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new

global challenges in the era of paediatric HIV elimination. Lancet Infect Dis

- 728 [Internet]. 2016 Jun;16(6):e92–107. Available from: 729 https://linkinghub.elsevier.com/retrieve/pii/S1473309916000554 730 33. Kuhn L, Coutsoudis A, Moodley D, et al. T-helper cell responses to HIV 731 envelope peptides in cord blood: protection against intrapartum and breast-732 feeding transmission. AIDS [Internet]. 2001 Jan 5;15(1):1-9. Available from: 733 http://www.ncbi.nlm.nih.gov/pubmed/11192849 734 Holditch SJ, Eriksson EM, Tarosso LF, et al. Decay kinetics of HIV-1 specific T 34. 735 cell responses in vertically HIV-1 exposed seronegative infants. Front Immunol 736 [Internet]. 2011;2:94. Available from: 737 http://www.ncbi.nlm.nih.gov/pubmed/22566883 738 35. Huo Y, Patel K, Scott GB, et al. Lymphocyte subsets in HIV-exposed 739 uninfected infants and HIV-unexposed uninfected infants. J Allergy Clin 740 Immunol [Internet]. 2017 Aug;140(2):605-608.e3. Available from: 741 https://linkinghub.elsevier.com/retrieve/pii/S009167491730338X 742 36. Borges-Almeida E, Milanez HM, Vilela MMS, et al. The impact of maternal HIV 743 infection on cord blood lymphocyte subsets and cytokine profile in exposed 744 non-infected newborns. BMC Infect Dis [Internet]. 2011 Dec 3;11(1):38. 745 Available from: http://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-746 2334-11-38 747 Waitt C. Orrell C. Walimbwa S. et al. Safety and pharmacokinetics of 37. 748 dolutegravir in pregnant mothers with HIV infection and their neonates: A 749 randomised trial (DolPHIN-1 study). Mofenson LM, editor. PLOS Med
- 751 https://dx.plos.org/10.1371/journal.pmed.1002895

752 38. Kreitchmann R, Schalkwijk S, Best B, et al. Efavirenz pharmacokinetics during

[Internet]. 2019 Sep 20;16(9):e1002895. Available from:

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776


pregnancy and infant washout. Antivir Ther [Internet]. 2018;24(2):95–103. Available from: https://www.intmedpress.com/journals/avt/abstract.cfm?id=3283&pid=48 39. Pacheco SE, McIntosh K, Lu M, et al. Effect of Perinatal Antiretroviral Drug Exposure on Hematologic Values in HIV-Uninfected Children: An Analysis of the Women and Infants Transmission Study. J Infect Dis [Internet]. 2006 Oct 15;194(8):1089–97. Available from: https://academic.oup.com/jid/articlelookup/doi/10.1086/507645 40. Bonney EA, Pudney J, Anderson DJ, Hill JA. Gamma-Delta T Cells in Midgestation Human Placental Villi. Gynecol Obstet Invest [Internet]. 2000;50(3):153–7. Available from: https://www.karger.com/Article/FullText/10315 41. Pique-Regi R, Romero R, Tarca AL, et al. Single cell transcriptional signatures of the human placenta in term and preterm parturition. Elife [Internet]. 2019 Dec 12;8. Available from: https://elifesciences.org/articles/52004 42. Ernst LM. Maternal vascular malperfusion of the placental bed. APMIS [Internet]. 2018 Jul;126(7):551–60. Available from: http://doi.wiley.com/10.1111/apm.12833 Weckman AM, Ngai M, Wright J, McDonald CR, Kain KC. The Impact of 43. Infection in Pregnancy on Placental Vascular Development and Adverse Birth Outcomes. Front Microbiol [Internet]. 2019 Aug 22;10. Available from: https://www.frontiersin.org/article/10.3389/fmicb.2019.01924/full


### Table 1: Maternal and infant characteristics


	HIV-Uninfected N=9	HIV-Infected N=21	P-Value
Age, years			1.0
≤24	1 (11.1)	2 (9.5)	
25-29	5 (55.6)	11 (52.4)	
≥30	3 (33.3)	8 (38.1)	
Median (IQR)	29 (25 - 31)	29 (26 - 30)	
Median gestation at enrolment	30 (26 - 32)	28 (28 - 31)	0.6
Gravidity			0.003
1	5 (55.6)	1 (4.8)	
2	3 (33.3)	7 (33.3)	
≥3	1 (11.1)	13 (61.9)	
Median (IQR)	1 (1 - 2)	3 (2 - 3)	
Infant Characteristics			
Sex			1.0
Female	6 (66.7)	12 (57.1)	
Male	3 (33.3)	6 (28.6)	
Missing	0 (0)	3 (14.3)	
Median gestation at delivery (completed weeks)	40 (40)	39 (38 - 39)	0.003
Birthweight in grams, Median (IQR)	3420 (3420 - 4000)	3305 (3010 - 3570)	0.07

Table 2: Placental characteristics and pathology at delivery

	HIV-Uninfected N=9	HIV-Infected N=21	P-Value
Placental basal plate weight (g), median (IQR)	468 (426 - 533)	394 (343 – 469)	0.02
Placental weight (g)			0.03
Small (<10 <sup>th</sup> percentile)	0 (0)	8 (38.1)	
Appropriate (10 - 90 <sup>th</sup> percentile)	9 (100.0)	12 (57.1)	
Large (>90 <sup>th</sup> percentile)	0 (0)	0 (0)	
Missing	0 (0)	1 (4.8)	
Fetal-Placenta weight ratio			0.02
Small (<10 <sup>th</sup> percentile)	1 (11.1)	0 (0)	
Appropriate (10 - 90 <sup>th</sup> percentile)	8 (88.9)	11 (52.4)	
Large (>90 <sup>th</sup> percentile)	0 (0)	7 (33.3)	
Missing	0 (0)	3 (14.9)	
Placenta greatest diameter (mm), median (IQR)	180 (172 - 210)	180 (170 - 199)	0.6
Placenta thickness (mm), median (IQR)	20 (15 -20)	25 (16.5 - 27.5)	0.2
Cord insertion			0.7
Central	3 (33.3)	3 (33.3)	
Off centre	5 (55.6)	12 (57.1)	
Marginal	1 (11.1)	5 (23.8)	
Missing	0 (0)	1 (4.76)	
Meconium exposure			0.1
+	3 (33.3)	2 (9.5)	
<del>-</del>	6 (66.7)	19 (90.5)	
Chorioamnionitis			
Maternal Inflammatory Response			0.6
+	2 (22.2)	2 (9.5)	
<del>-</del>	7 (77.8)	19 (90.5)	
Fetal Inflammatory Response			0.6
+	2 (22.2)	3 (14.3)	
-	7 (77.8)	18 (85.7)	
Chronic Deciduitis			0.5
+	0 (0)	2 (9.5)	
<u>-</u>	9 (100)	19 (90.5)	
Maternal Vascular Malperfusion			0.09
+	0 (0)	6 (28.6)	
-	9 (100)	15 (71.4)	
Villitis of Unknown Etiology			1.0
+	0 (0)	0 (0)	
<u>-</u>	9 (100)	21 (100)	









Absolute maternal CD4 at 28 weeks' gestation prior to ART (cells/mm³)

Figure 2








Figure 3

